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Background: We prospectively assessed the utility of intensity-modulated radiation therapy (IMRT) with urethral
dose reduction and a small margin between the clinical target volume (CTV) and the planning target volume (PTV)
for patients with localized prostate cancer.
Methods: The study population was 110 patients in low- (14.5%), intermediate- (41.8%), and high-risk (43.6%)
categories. Three gold fiducial markers were inserted into the prostate. A soft guide-wire was used to identify the
urethra when computed tomography (CT) scan for treatment planning was performed. A dose constraint of V70 <
10% was applied to the urethral region. Margins between the CTV-PTV were set at 3 mm in all directions. Patients
were treated with 70 Gy IMRT in 30 fractions (D95 of PTV) over 7.5 weeks. The patient couch was adjusted to keep
the gold markers within 2.0 mm from their planned positions with the use of frequent on-line verification.
Results: The median follow-up period was 31.3 (3.2 to 82.1) months. The biochemical relapse-free survival (bRFS)
rates at 3 years were 100%, 93.8% and 89.5% for the low-, intermediate-, and high-risk patients, respectively. The
incidences of acute adverse events (AEs) were 45.5% and 0.9% for grades 1 and 2, respectively. The late AEs were
grade 1 cystitis in 10.0% of the patients, rectal bleeding in 7.3%, and urinary urgency in 6.4%. Only three patients
(2.7%) developed grade 2 late AEs.
Conclusions: On-line image guidance with precise correction of the table position during radiotherapy achieved
one of the lowest AEs rates with a bRFS equal to the highest in the literature.
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Adverse eventBackground
The use of image-guided radiation therapy (IGRT) equip-
ment has been shown to reduce the adverse events on or-
gans at risk (OAR) near the clinical target volume (CTV)
in intensity-modulated radiation therapy (IMRT) [1,2]. For
prostate cancer, it has been demonstrated that the rate of* Correspondence: sshing@med.hokudai.ac.jp
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unless otherwise stated.complications involving the rectal wall (an OAR near the
CTV) can be reduced by using IGRT equipment [3]. How-
ever, it has been difficult to reduce the dose to the OAR
within the CTV with IMRT because of the uncertainty in
localization [4]. Complications caused by the urethra in
the prostate, which is regarded as an OAR within the
CTV, may be avoided by reducing the dose to the urethra
with precise real-time IGRT and by correcting the table
position during radiotherapy to reduce intra-fractional
positional errors.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 Characteristics of the 110 localized prostate
cancer patients
Characteristic No. of patients (%)










<10 ng/mL 60 (54.5%)
10–19.9 ng/mL 26 (23.6%)









70 Gy/30 Fr(D95) 101
75 Gy/30 Fr(Iso) 5
65.3 Gy/28 Fr(D95) 3
67.5 Gy/29 Fr(Iso) 1
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http://www.ro-journal.com/content/9/1/118We have reported a real-time tumor-tracking radiation
therapy (RTRT) system [5] which uses the implantation of
fiducial markers and two sets of room-mounted fluoros-
copy. This system can maintain accuracy within nearly
2 mm during radiotherapy by reducing the intra-fractional
as well as inter-fractional errors, and it could also be called
on-line image-guided radiotherapy with intra-fractional
correction (intra-IGRT) [6]. We have not yet encountered
any situation in which the precision of intra-IGRT would
be required rather than non-intra-IGRT technologies that
do not improve intra-fractional accuracy but do improve
inter-fractional accuracy (inter-IGRT).
We postulated that a combination of intra-IGRT and
IMRT would enable a reduction of the dose to the urethra
in the prostate while maintaining the required dose to the
prostate, compared to inter-IGRT technologies which only
have inter-fractional image guidance and table correction
capability.
To test our hypothesis, we started a prospective study in
2004. Newly devised procedures in treatment planning
were developed and implemented in the treatment protocol
to identify soft structures (e.g., bladder neck and urethral
tract) in the prostate which are movable during radiother-
apy. The primary end-point was the incidence of AEs. A




One hundred-ten consecutive localized prostate cancer
patients (median age, 70 years; range 52 to 79) treated be-
tween Dec. 2004 and Nov. 2011 were included. The charac-
teristics of the patients are shown in Table 1. They were
categorized into low- (14.5%; n = 16), intermediate- (41.8%;
n = 46), and high-risk (43.6%; n = 48) groups according to
the National Comprehensive Cancer Network (NCCN)
guidelines [7]. All but three patients received the total dose
as planned in the protocol; one received 29 fractions, and
two received 28 fractions instead of 30 fractions because of
the comorbidity of severe vascular diseases. The median
follow-up period was 31.3 months (3.2 to 82.1) for all
patients. Following local Ethics Committee (the ethical
committee of Hokkaido University Graduate School of
Medicine) approvals patients were enrolled this study and
written informed consent was obtained from all the pa-
tients prior to treatment.
Treatment
Three gold fiducial markers were inserted into the pros-
tate of each patient, for tumor localization [8]. The three
markers (2.0 mm dia.) were inserted into the patient's
prostate gland one week before the CT for treatment plan-
ning. To ensure a constant bladder volume, an intravesical
instillation of 100 mL of sterile normal saline was followedby CT scanning of the small pelvis with the patient in the
supine position on a flat carbon table. A soft guide-wire
(0.46 mm dia.) was inserted into the urethra through a ur-
ethral catheter (4.0 mm dia.) when the CT scan was per-
formed. Magnetic resonance imaging (MRI) was also
obtained with the urethral catheter in place (Figure 1 left).
In total, (a) CT images with the catheter/guide-wire in
the urethra tract, (b) CT images with the guide-wire only
in the urethra tract, and (c) MRI without the catheter/
guide-wire were all used for each patient's treatment plan-
ning. All of the images were transferred to a treatment
planning system (TPS), XiO (CMS, St. Louis, MO from
2004.4 to 2007.9) or Pinnacle3 (Hitachi Medical Co.,
Tokyo from 2007.10 to 2011.11) and fused according to
the location of the three implanted markers. The image
fusion was performed according to the fiducial markers,
not by the bony structures, nor by the soft tissues. For the
MR images, spotty signal voids caused by the gold markers
were used to match them to the high-density signals on
CT images. The gold markers did not make any apparent
distortion of MRI.
The contours of the prostate gland including the urethra
were defined as the CTV for all patients. The CTV in-
cluded the prostate and seminal vesicles for the high-risk
group and for intermediate-risk patients who had any two
of the following three factors: T2b or higher T stage, mod-
erately differentiated adenocarcinoma in pathological diag-
nosis, and initial prostate-specific antigen (PSA) ≥10. The
Figure 1 MRI image fusion for treatment planning and dose distribution for urethra dose controlled IMRT planning. MRI image fusion is
used for treatment planning (left image). IMRT planning is performed with the constraint that urethra dose will not exceed V70Gy > 10%
generally (right image).
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expansion of the CTV with the addition of a 3-mm
margin.
The total dose of radiation treatment was prescribed at
the dose covering 95% of the PTV (D95). Seventy Gy 7-
field IMRT in 30 fractions (D95 of PTV) over 7.5 weeks
was used for almost all the patients. This dose was se-
lected to be equal to our previous treatment, 75 Gy at
2.5 Gy per fraction prescribed at the isocenter. Six patients
were prescribed the dose at the isocenter at the beginning
of this treatment. For four patients, the fraction number
was reduced one or two times to satisfy the dose con-
straint. The urethra as an OAR was contoured in 2 mm
diameter Region of interest (ROI) with reference to the
guide-wire that appeared on the CT images. A margin of
2 mm was applied to the urethra (OAR) to determine the
planning organ at risk volume (PRV) (OAR+margin). A
dose constraint of V70Gy < 10% was applied to the PRV of
the urethral region (4 mm dia.) along the catheter in the
prostate represented on the CT images (Figure 1 right).
The dose constraint was not used for the location when a
discrepancy between (a) the catheter/guide-wire in CT and
(b) the guide-wire only in CT was observed; this is because
a discrepancy suggests a soft and movable nature of the lo-
cation and a higher risk of misalignment of the urethra
during irradiation. Bladder neck was the most movable
location; details of the anatomical changes observed
will be presented elsewhere. Other dose constraints
were rectal V60 Gy < 20%, rectal V37.5 Gy < 50%, and
bladder V37.5 Gy < 30%.
The detail of the on-board imaging used in this study has
been described previously [8]. Basically observation through
the diagnostic X-ray can be made real time during thera-
peutic beam delivery. And calculations for the localizationof the target accuracy were made 7.6 times on average at
one-day treatment. The incidence of the couch adjustment
required were differ patients to patients; 6 to 68 (median
19) times position adjustment during the 30 fractions treat-
ment for a patient.
All radiotherapy was performed without the catheter/
guide-wire insertion. The catheter/guide-wire was not
inserted during radiotherapy since the guide-wire was
shown to represent the urethral position only in our pre-
paratory studies during image acquisition. All seven ports
were treated in each daily treatment. Using frequent on-
line verification with the RTRT system during treatment at
least at the start of every portal irradiation, the patient
couch was adjusted on-line to keep the gold markers
within 2.0 mm from their planned positions. For the pa-
tients who moved during irradiation, continuous fluoro-
scopic observation was used and the irradiation was
automatically interrupted when the marker moved more
than 2.0 mm. Patients are asked to void a few hours before
every radiotherapy. The details of this procedure were as
reported [6,8].
Hormonal treatment was accepted as a neo-adjuvant
and/or concomitant treatment during radiotherapy for 34
patients (27 high-risk, 6 intermediate-risk, and 1 low-risk).
Assessments and statistical analysis
Patients were followed by both the referring urologist and
a radiation oncologist every 3 months after the treatment.
After 5 years, the follow-up interval was changed to once
a year. Acute and late AEs were scored according to the
Common Toxicity Criteria Adverse Events version 4
(CTCAE v4.0) scale. Acute AE was defined as an AE ori-
ginating within 90 days from the completion of radiation
therapy. Late AE was defined as AE appearing more than
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chemical relapse-free survival (bRFS) was defined as the
time between the first day of radiotherapy and the date of
biochemical failure as defined by the Phoenix definition
(nadir of PSA + 2 ng/mL) or death from any cause.
A comparative study of the doses to the urethra and CTV
was added as an additional study for 77 patients whose treat-
ment plans were made with the Pinnacle3 TPS after 2007.
Each minimum, maximum, and mean dose was compared
with the adverse events. All statistical analyses were per-
formed using JMP 9.0.3 (SAS Institute, Cary, NC, USA).Results
The incidences of acute gastrointestinal (GI) AEs were 7
(6.4%) for grade 1 (Table 2). A late grade 1 GI AE was ob-
served in 8 (7.3%) patients. No acute and late grade 2 or
higher-grade GI AE was observed.
The incidences of acute genitourinary (GU) AEs were
44 (40.0%) for grade 1 and 1(0.9%) for grade 2. Acute
grade 1 voiding frequency and cystitis were observed in 30
(27.3%) and 27 (24.5%) patients, respectively. Acute grade
2 voiding frequency and urgency were observed in 1
(0.9%) and 1 (0.9%) patient, respectively. Late grade 1 and
grade 2 GU AEs were observed in 17 (15.5%) and 3 (2.7%)
patients, respectively. No grade 3 or higher-grade acute or
late toxicity was observed.
The bRFS rates at 3 years were 100%, 93.8% and 89.5%;
at 5 years were 100%, 84.0% and 79.6% for the low-,
intermediate-, and high-risk patients respectively (Figure 2).
Hormonal treatment was accepted as a neo-adjuvant and/
or concomitant treatment during radiotherapy for 34 pa-
tients (27 high-risk, 6 intermediate-risk, and 1 low-risk).
Of the 110 patients, 2 patients died; 1 patient from















Urethral tract pain 12
GI, gastrointestinal; GU, genitourinary. Acute (AE): originating within 90 days from th
from the completion of radiation therapy.cancer with metastasis to the lung and bone on day 441
without biochemical failure (Figure 3).
In the comparison of the dose to the CTV and the
urethra, there was no significant difference between the
minimum dose of CTV (67.76 Gy ± 0.75 Gy) and that of
urethra (67.96 ± 0.65 Gy) (p = .073). There was significant
difference between the maximum dose of CTV (75.40 ±
1.23 Gy) and that of urethra (71.47 ± 1.16 Gy) (p < 0.001)
and the mean dose of CTV (72.58 ± .65 Gy) and urethra
(69.29 ± 0.53 Gy) (p < 0.001), respectively. The medical
mean dose to the PTV including the urethral region
ranged from 71.34 to 72.52 Gy (Figure 4). There was no
relationship between the minimum or mean dose and the
bRFS, or between the maximum dose of the CTV or ur-
ethral region and the urethral adverse events in the dose
range in our study.
Discussion
Kupelian et al. published excellent results of their hypo-
fractionated IMRT study in which the nominal prescrip-
tion dose was 70 Gy in 28 fractions [9]. In a linear-
quadratic model, the α/β ratio for prostate cancer was re-
ported to be smaller than those of acute-responding tis-
sues and estimated as 1.5 by Brenner et al. [10]. If we
assume that the α/β ratio is 1.5 for prostate cancer, 70 Gy
in 28 fractions is equivalent to a biological effective dose
(BED) of 187 Gy, or 85 Gy using a daily dose of 1.8 Gy.
Our schedule is similar to their schedule and to their bio-
logical dose, since the mean dose of CTV in the present
study, 72.58 Gy in 30 fractions, is equivalent to a BED of
190 Gy or 86.4 Gy in 48 fractions.
The primary end-point of our study was the incidence
of adverse events. Kupelian et al. showed that the acute GI
toxicity was grade 1 in 40% of their patients and grade 2
in 9%; late GI toxicity was grade 1 in 5.9%, grade 2 inte cancer patients (n = 110)
Late
2 3 0 1 2 3
0 0 102 8 0 0
% 0% 92.7% 7.3% 0% 0%
8
1 0 90 17 3 0





e completion of radiation therapy. Late (AE): appearing more than 90 days
Figure 2 Overall bRFS (biological relapse-free survival) for all 110 prostate cancer patients.
Shimizu et al. Radiation Oncology 2014, 9:118 Page 5 of 8
http://www.ro-journal.com/content/9/1/1183.1%, grade 3 in 1.3%, and grade 4 in 0.1%. We showed
that acute GI toxicity was grade 1 in 6.4% of our patients,
and late GI toxicity was grade 1 in 7.3%; no grade 2 or
higher toxicity was observed. Kupelian et al. reported that
acute GU toxicity was grade 1 in 48% of their patients,
grade 2 in 18%, and grade 3 in 1%; late GU toxicity was
grade 1 in 4.3%, grade 2 in 5.1%, and grade 3 in 0.1%. In
our patient population, we observed that the acute GU
toxicity was grade 1 in 40% and grade 2 in 0.9%, and late
GU toxicity was grade 1 in 15.5% and grade 2 in 2.7%. No
grade 3 or higher toxicity was observed.
Table 3 illustrates the results of hypofractionated radio-
therapy for prostate cancer in recent publications. The
volumes of CTV, which depend on the treatment policy,
and the lengths of PTV margin, which depend on the posi-
tioning accuracy, were also shown in the table. At a glance,
the incidence of complications seems to be related to the
volume of CTV and the length of PTV margin [9,11-13].
As for the toxicity scale, Fonteyne et al. mentioned thatFigure 3 Overall bRFS for patients with/without hormonal therapy.there is a need for a uniform toxicity scoring system for our
radiotherapy community, because each toxicity scale such
as RTOG, SOMA/LENT and CTC toxicity scale lacks im-
portant symptoms [14]. They also described that the omis-
sion of the symptoms leads to underreporting of toxicity
and the incidence of late GU toxicity is influenced by the
toxicity scale that is used. So it is difficult to compare our
results with those of other institutions, the very low inci-
dence of toxicity in the present study might be attributable
to the small PTV-CTV margin, the reduction in the ureth-
ral dose, and the reduction in intra-fractional error due to
organ motion. Further observation for more long period
and more in number, however, is required for obtaining
firm conclusion.
Our secondary end-point was the bRFS. The 5-year rates
for the patients with low-, intermediate-, and high-risk
disease were 97%, 93%, and 75%, respectively in Kupelian's
study [9]. Although the confidence interval is still too
large, the present bRFS results for the low-, intermediate-,













Nominal dose (Gy)/no. of fractions 62/20 56/16 70/28 60/20 57/19 70/30
Number of patients 83 113 770 153 151 110
Follow-up period (months) 35 47 45 51 31
CTV for T1-2 & low risk Prostate & seminal
vesicles
Prostate only Prostate only Prostate + base of
seminal vesicles
Prostate only








PTV margin (mm) Craniocaudal 10 3-10 5 5 5 3
Anterior 10 5 5 5 3
Lateral 10 8 5 5 3
Posterior 6 4 0 0 3
Early GU (%) G2 46 38 18 8 7 1
G3 1 0 1 0 0 0
G4 0 0 0 0 0
Early GI (%) G2 35 10 9 2 1 0
G3 0 4 0 0 0 0
G4 0 0 0 0 0
Late GU (%) G2 8 10 5 2 0 3
G3 0 4 1 0 0 0
G4 1 0 0 0 0
Late GI (%) G2 14 7 3 4 1 0
G3 1 2 1 0 0 0
G4 0 0 0 0 0
Biochemical relapse
free survival 5 yrs (3 yrs) %
Low - 98 94 - - 100 (100)
Intermediate - 93 83 - - 84 (94)
High - 82 72 - - 80 (90)
Figure 4 Histogram of the CTV dose and the urethra dose.
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as effective as Kupelian et al.'s outcome and those in other
reports so far [2-4,11,15,16]. Kupelian et al. used an ultra-
sound system to reduce the inter-fractional set-up error
and adapted a PTV-CTV margin of 4 mm posteriorly,
8 mm laterally, and 5 mm in all other directions. Crehange
et al. recently showed that a 5-mm margin in all directions
is also acceptable with the use of an ultrasound system [3].
To the best of our knowledge, the present study is the
first one suggesting that image-guided IMRT with an
only 3-mm PTV-CTV margin may achieve a bRFS rate
equivalent to those of previous series using the same
end-point. In this study, we restricted the urethral dose
by using V70Gy < 10% as the dose constraint for its PRV,
to reduce hot spots in the urethral region. It should be
noted that we kept the minimum CTV dose at 67.76 Gy ±
0.75 Gy (which is equivalent to 85 Gy using 1.8 Gy), and
we did not reduce the urethral dose further, to avoid
increasing the risk of tumor relapse around the urethra.
Zelefsky et al. reported reductions in acute and late
GU toxicity without compromising PSA relapse-free sur-
vival achieved by the implantation of fiducial markers
and inter-IGRT [2]. They attributed the reduced inci-
dence of urinary toxicity to the reduction of the dose
and volume to the bladder and bladder neck region. Our
results are consistent with their suggestion that the re-
duction of doses to these regions is important to reduce
frequent urination and urgency. Obstruction of voiding
is also known as a late GU toxicity [10]. Coen et al. sug-
gested the possibility of reducing the dose to the urethra
as a new strategy to improve radiotherapy for prostate
cancer [17]. The findings of the present study suggest
that a treatment technique that reduces the dose to the
urethra running through the prostate gland can reduce
the late toxicity of urethral stricture and obstruction.
Vainshtein et al. recently reported the use of urethra-
sparing IMRT with daily pretreatment orthogonal im-
aging for set-up [18]. They compared the clinical out-
comes between eight patients with normal IMRT and
eight patients with urethra dose-sparing IMRT. They
reported that there was no PSA failure in the normal
IMRT patients, but 3 of the 8 patients in the urethra
dose-sparing IMRT group experienced PSA relapse.
The three PSA relapses were at the peripheral zone at
the opposite side of the primary site, and not in the
dose reduction area around the urethra. Therefore, it
cannot be concluded from the Vainshtein et al. study
that the urethra dose-sparing is the direct cause of PSA
recurrence. In addition, as those authors noted, the
intra-fractional position correction was not performed
in their treatment; this could be a cause of the high
PSA failure rate and may have had no benefit in redu-
cing GU toxicity. The present study suggests that ur-
ethra dose-sparing IMRT itself is not a harmful as longas both proper treatment planning procedure and
intra-fractional position correction are used.
For AEs, Fonteyne et al. recently reported that probabil-
ity of developing Grade2, Grade3/4 GI and GU AEs [19],
at the point of 24-36month actuarial risk may indicate us
the outlook for the incidence of developing long term
AEs. However, we must be careful since there is a ten-
dency of increasing GU toxicity with time even after 6–8
years. It should be noted that the median follow up period
of this study is still too short to make any firm conclusion
of the long term results for both bRFS and AEs.
Conclusions
IMRT with urethra dose reduction and precise target
localization during irradiation using intra-IGRT for intra-
fractional guidance achieved very low incidences of acute
and late GI and GU toxicity. In addition, the small margin
around the CTV and the dose reduction around the ur-
ethra did not result in a high PSA failure rate. We have
elucidated the clinical benefits of on-line image guidance
with the precise correction of the table position during
radiotherapy.
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